医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2013年
30期
133-135
,共3页
蒋跃根%应葳%马鹏程%陶松宁%王峰来%仇宁(通讯作者)
蔣躍根%應葳%馬鵬程%陶鬆寧%王峰來%仇寧(通訊作者)
장약근%응위%마붕정%도송저%왕봉래%구저(통신작자)
阿卡波糖%糖尿病%降糖作用%血糖波动%不良反应
阿卡波糖%糖尿病%降糖作用%血糖波動%不良反應
아잡파당%당뇨병%강당작용%혈당파동%불량반응
Arcarbose%Diabetes%Glucose-decreasing effect%Blood glucose excursion%Side effects
目的:观察健康男性志愿者口服浙江海正药业股份有限公司生产的阿卡波糖片后血葡萄糖(GLU)变化及急性毒副作用。方法对40名健康男性志愿者单独服用蔗糖及蔗糖、阿卡波糖同时服用后,0、0.25、0.5、0.75、1、1.5、2、2.5、3、3.5、4h的血糖连续监测,并检测服用阿卡波糖前后血生化指标:葡萄糖(GLU)、丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、尿素(Urea)、肌酐(Cr);血液分析指标:红细胞(RBC)、白细胞(WBC)、血小板(PLT)、血红蛋白(Hb)的改变。结果蔗糖单独服用,血糖平均最低浓度(Cmin )为4.26±0.67 mmol/L,血糖平均最高浓度(Cmax)为8.04±1.06 mmol/L,4h血糖时间曲线下面积(AUC (0-4))为21.73±2.48 mmol/L/h。蔗糖、阿卡波糖同时服用,血糖Cmin为4.7±0.32 mmol/L,血糖Cmax为5.88±0.77 mmol/L,AUC (0-4)为20.14±1.53 mmol/L/h,血糖浓度明显降低,在0.25、0.5、0.75、1、2.5、3、3.5h有极显著性差异(p<0.01),在4h有显著性差异(p<0.05)。蔗糖单独服用,血糖漂移(GE)为4.44±1.28 mmol/L,血糖坪浓度(Css)为5.43±0.62mmol/L。蔗糖、阿卡波糖同时服用GE为1.55±0.78 mmol/L,Css为5.14±0.38mmol/L,两者均降低,有极显著性差异(p<0.01)。除67.5%的受试者出现不同程度的腹泻或腹胀外,无明显不良反应。结论阿卡波糖有明显的降糖作用,能够有效地控制餐后血糖,并且改善餐后血糖波动,平稳血糖,值得临床推广运用。
目的:觀察健康男性誌願者口服浙江海正藥業股份有限公司生產的阿卡波糖片後血葡萄糖(GLU)變化及急性毒副作用。方法對40名健康男性誌願者單獨服用蔗糖及蔗糖、阿卡波糖同時服用後,0、0.25、0.5、0.75、1、1.5、2、2.5、3、3.5、4h的血糖連續鑑測,併檢測服用阿卡波糖前後血生化指標:葡萄糖(GLU)、丙氨痠氨基轉移酶(ALT)、天門鼕氨痠氨基轉移酶(AST)、尿素(Urea)、肌酐(Cr);血液分析指標:紅細胞(RBC)、白細胞(WBC)、血小闆(PLT)、血紅蛋白(Hb)的改變。結果蔗糖單獨服用,血糖平均最低濃度(Cmin )為4.26±0.67 mmol/L,血糖平均最高濃度(Cmax)為8.04±1.06 mmol/L,4h血糖時間麯線下麵積(AUC (0-4))為21.73±2.48 mmol/L/h。蔗糖、阿卡波糖同時服用,血糖Cmin為4.7±0.32 mmol/L,血糖Cmax為5.88±0.77 mmol/L,AUC (0-4)為20.14±1.53 mmol/L/h,血糖濃度明顯降低,在0.25、0.5、0.75、1、2.5、3、3.5h有極顯著性差異(p<0.01),在4h有顯著性差異(p<0.05)。蔗糖單獨服用,血糖漂移(GE)為4.44±1.28 mmol/L,血糖坪濃度(Css)為5.43±0.62mmol/L。蔗糖、阿卡波糖同時服用GE為1.55±0.78 mmol/L,Css為5.14±0.38mmol/L,兩者均降低,有極顯著性差異(p<0.01)。除67.5%的受試者齣現不同程度的腹瀉或腹脹外,無明顯不良反應。結論阿卡波糖有明顯的降糖作用,能夠有效地控製餐後血糖,併且改善餐後血糖波動,平穩血糖,值得臨床推廣運用。
목적:관찰건강남성지원자구복절강해정약업고빈유한공사생산적아잡파당편후혈포도당(GLU)변화급급성독부작용。방법대40명건강남성지원자단독복용자당급자당、아잡파당동시복용후,0、0.25、0.5、0.75、1、1.5、2、2.5、3、3.5、4h적혈당련속감측,병검측복용아잡파당전후혈생화지표:포도당(GLU)、병안산안기전이매(ALT)、천문동안산안기전이매(AST)、뇨소(Urea)、기항(Cr);혈액분석지표:홍세포(RBC)、백세포(WBC)、혈소판(PLT)、혈홍단백(Hb)적개변。결과자당단독복용,혈당평균최저농도(Cmin )위4.26±0.67 mmol/L,혈당평균최고농도(Cmax)위8.04±1.06 mmol/L,4h혈당시간곡선하면적(AUC (0-4))위21.73±2.48 mmol/L/h。자당、아잡파당동시복용,혈당Cmin위4.7±0.32 mmol/L,혈당Cmax위5.88±0.77 mmol/L,AUC (0-4)위20.14±1.53 mmol/L/h,혈당농도명현강저,재0.25、0.5、0.75、1、2.5、3、3.5h유겁현저성차이(p<0.01),재4h유현저성차이(p<0.05)。자당단독복용,혈당표이(GE)위4.44±1.28 mmol/L,혈당평농도(Css)위5.43±0.62mmol/L。자당、아잡파당동시복용GE위1.55±0.78 mmol/L,Css위5.14±0.38mmol/L,량자균강저,유겁현저성차이(p<0.01)。제67.5%적수시자출현불동정도적복사혹복창외,무명현불량반응。결론아잡파당유명현적강당작용,능구유효지공제찬후혈당,병차개선찬후혈당파동,평은혈당,치득림상추엄운용。
Objective To investigate glucose-decreasing effect and acute side effects of therapy of acarbose made in Haizheng pharmaceutical company of Zhejiang province on healthy male volunteers. Methods After taken sucrose with acarbose and taken sucrose singly, blood glucose were continuous monitored by 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours, while biochemical indicators GLU, ALT, AST,Urea, Cr and blood component indexes RBC, WBC, PLT, and Hb were also detected. Results Blood glucose Cmin, Cmax and AUC (0-4) were 4.26±0.67 mmol/L, 8.04±1.06 mmol/L and 21.73±2.48 mmol/L/h respectively when sucrose was singly taken, while Blood glucose Cmin, Cmax and AUC (0-4) were 4.7±0.32 mmol/L, 5.88±0.77 mmol/L, 20.14±1.53 mmol/L/h respectively when sucrose was taken with arcarbose. Blood glucose was reduced obviously and there were very significant differences on 0.25, 0.5, 0.75, 1, 2.5, 3, 3.5 hours (P< 0.01). There was significant difference on 4 hours (P< 0.05). GE was 4.44±1.28 mmol/L and Css was 5.43±0.62mmol/L when sucrose was taken singly, while GE was 1.55±0.78 mmol/L and Css was 5.14±0.38mmol/L when sucrose was taken with arcarbose. They were both reduced and had very significant differences ( P< 0.01). Except for 67.5% participants exhibited bel yache or diarrhoea at different degrees, there was no obvious side effects. Conclusions Arcarbose has obvious glucose-decreasing effect and control post-prandial glycemia effectively. It ameliorates blood glucose excursion, stabilizes blood glucose, and deserves clinical applications.